The $30M financing removes near-term bankruptcy risk but dilutes shareholders significantly. Monitor FemBloc FINALE trial enrollment updates and FemaSeed revenue trajectory in coming quarters for signs of commercial traction. The stock's micro-cap status and historical negative drift suggest high risk; any positive catalyst from FemBloc data could drive outsized moves.
Price Chart
Executive Summary
Femasys reported Q2 2026 revenue of $331,827, down 18.9% YoY, with a net loss of $4.47M ($1.33/share). The EPS beat consensus by 14.3% due to lower share count and non-cash gains, but the core business weakened. The $30M private placement completed post-quarter provides a cash runway to execute commercial strategy for FemaSeed and advance FemBloc trials, offsetting the revenue decline and dilutive overhang.
Key Financial Metrics
Key Facts
- Q2 2026 revenue fell 18.9% YoY to $331,827, driven by lower FemVue sales.
- Net loss improved to $4.47M ($1.33/share) vs $4.59M ($3.18/share) a year ago, aided by non-cash gains on warrant and conversion option liabilities.
- EPS of -$1.33 beat consensus of -$1.40 by 14.3%, but the beat was driven by non-operating items, not operational improvement.
- Post-quarter, the company closed a $30M private placement with potential proceeds up to $90M upon full warrant exercise.
- Cash and equivalents stood at $1.4M as of June 30, 2026, with an accumulated deficit of $149.4M.
- Regained Nasdaq compliance and appointed John Canning as COO.
- Received CE Mark for FemHSG Catheter and launched FemaSeed Complete at ACOG 2026.
Financial Impact
Revenue declined $77K (-18.9%) YoY; net loss improved $117K; $30M private placement provides liquidity but dilutes existing shareholders.
Risk Factors
- Revenue decline of 18.9% YoY signals weak commercial execution for FemVue.
- Dilution from the $30M private placement and potential warrant exercises will pressure EPS.
- Accumulated deficit of $149.4M and minimal cash ($1.4M pre-financing) highlight ongoing capital needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345606 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Press Release | $1.67 | awaiting T+5 | — | $1.43 (−14.37%) |
Oct 15, 2026 10d ago | SC 13G | $1.74 $1.56 | ▼ −10.09% | ▼ −9.07% | $1.43 (−17.58%) |
Sep 29, 2026 27d ago | EFFECT | $2.09 $2.08 | ▲ +0.48% | ▲ +2.43% | $1.43 (+31.58%) |
Aug 14, 2026 10w ago | 8-K | $2.16 $2.98 | ▼ −37.96% | ▼ −39.15% | $1.43 (+33.80%) |
Aug 14, 2026 10w ago | Press Release | $2.16 $2.98 | ▲ +37.96% | ▲ +39.15% | $1.43 (−33.80%) |
Aug 11, 2026 10w ago | Insider Cluster | $2.35 $2.71 | ▲ +15.32% | ▲ +15.76% | $1.43 (−39.15%) |
Aug 7, 2026 11w ago | Press Release | $2.66 $2.29 | ▲ +13.91% | ▲ +14.31% | $1.43 (+46.24%) |
Jun 4, 2026 20w ago | 8-K | $7.14 $4.78 | ▼ −33.05% | ▼ −30.50% | $1.43 (−79.97%) |
May 13, 2026 23w ago | 8-K | $7.61 $6.75 | ▼ −11.38% | ▼ −10.66% | $1.43 (−81.21%) |
May 8, 2026 24w ago | 8-K | $8.08 $7.26 | ▼ −10.24% | ▼ −10.16% | $1.43 (−82.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers